Thursday, May 19, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home News

Toxin-producing yeast strains may damage the gut of patients with inflammatory bowel disease

by Medical Finance
in News
Toxin-producing yeast strains may damage the gut of patients with inflammatory bowel disease
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

Individual Candida albicans yeast strains in the human gut are as different from each other as the humans that carry them, and some C. albicans strains may damage the gut of patients with inflammatory bowel disease (IBD), according to a new study from researchers at Weill Cornell Medicine. The findings suggest a possible way to tailor treatments to individual patients in the future.

The researchers, who report their findings March 16 in Nature, used an array of techniques to study strains, or genetic variants, of Candida from the colons of people with or without ulcerative colitis, a chronic, relapsing and remitting inflammatory disorder of the colon and rectum and one of the main forms of IBD. They found that certain strains, which they call “high-damaging,” produce a potent toxin called candidalysin that damages immune cells.

“Such strains retained their “high-damaging” properties when they were removed from the patient’s gut and triggered pro-inflammatory immunity when colonized in mice, replicating certain disease hallmarks,” said senior author Dr. Iliyan Iliev, an associate professor of immunology in medicine in the Division of Gastroenterology and Hepatology and a scientist in the Jill Roberts Institute for Research in Inflammatory Bowel Disease at Weill Cornell Medicine.

IBD affects approximately 3.1 million people in the United States and can greatly impair patients’ quality of life. Such patients rely on a handful of available therapies, but treatments may not always be effective. The new study has suggested one reason steroids, a commonly used treatment, may not work; treating mice with the drug to suppress intestinal inflammation failed in the presence of “high-damaging” C. albicans strains.

Our findings suggest that C. albicans strains do not cause spontaneous intestinal inflammation in a host with intact immunity. But they do expand in the intestines when inflammation is present and can be a factor that influences response to therapy in our models and perhaps in patients.”


Dr. Iliyan Iliev, Senior Author

Most studies of the human microbiome in healthy individuals and those with IBD have focused on bacteria and viruses, but recent research by Dr. Iliev and others has illuminated the contributions of fungi to the effects of microbes on humans and mice. They have found that intestinal fungi play an important role in regulating immunity at surfaces exposed to the outside, such as the intestines and lungs, due to their potent immune-stimulating characteristics. While the collective community of fungi in the body, known as the mycobiota, has been linked to several diseases, including IBD, researchers previously had not understood the mechanisms by which the mycobiota contribute to inflammation in the gut.

In the new study, the investigators initially found that Candida strains, while highly diverse in the intestines of both patients with and without colitis, were on average more abundant in the patients with IBD. But that did not explain disease outcomes in individual patients. So, the investigators set out to identify the characteristics of these strains that cause damage and how they relate to individual patients.

The researchers observed that in the patients with ulcerative colitis, severe disease was associated with the presence of “high-damaging” Candida strains, which turned out to have a key factor in common: all produce the candidalysin toxin. The scientists showed that the toxin damages immune cells called macrophages, prompting a storm of the pro-inflammatory cytokine IL-1β.

To underscore this strain-specific effect, the researchers grew macrophages in the presence of Candida strains and found that the ability of the strains to induce IL-1β corresponded closely to the severity of colitis in the patients.

“Our finding shows that a cell-damaging toxin candidalysin released by “high damaging” C. albicans strains during the yeast-hyphae morphogenesis triggers pathogenic immunological responses in the gut,” said the first author Dr. Xin Li, who was a Charles H. Revson Postdoctoral Fellow in the Iliev laboratory at the time of the study.

Experiments in mice delineated that candidalysin-producing “high-damaging” strains induced the expansion of a population of T cells called Th17 cells and other immune cells associated with inflammation, such as neutrophils.

“Neutrophils contribute to tissue damage and their accumulation is a hallmark of active IBD,” said Dr. Ellen Scherl, the Jill Roberts Professor of Inflammatory Bowel Disease at Weill Cornell Medicine and a gastroenterologist at NewYork-Presbyterian/Weill Cornell Medical Center. “The indication that these processes might in part be driven by a fungal toxin released by yeast strains in specific patients could potentially inform personalized treatment approaches.”

Consistent with this finding, blocking IL-1β signaling had a dramatic effect in reducing colitis signs in mice that harbored these highly pro-inflammatory strains. The researchers noted that other recent studies have linked IBD to IL-1β in a general way, prompting ongoing investigations of drugs targeting related pathways as potential IBD therapies.

“We do not know whether specific strains are acquired by specific patients during the course of disease or whether they have been always there and become a problem during episodes of active disease” Dr. Iliev said. “Nevertheless, our findings highlight a mechanism by which commensal fungal strains can turn against their host and overdrive inflammation.”

The team is following up with studies of the mechanisms that drive the persistence of candidalysin-producing strains in the inflamed colon of specific IBD patients, as well as ways to choose patients for therapy targeting the mycobiome.

Source:

Journal reference:

Li, X.V., et al. (2022) Immune regulation by fungal strain diversity in inflammatory bowel disease. Nature. doi.org/10.1038/s41586-022-04502-w.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Bacterial biofilms use a developmental patterning mechanism seen in plants and animals

Study provides new insights into the communication of bacteria with their host

by Medical Finance
May 19, 2022
0

A newly discovered protein helps bacteria recognize stress hormones in the human body and direct their motion in the host....

Scientists unravel how blood cells mount the first line of defense against viruses

Single protein elicits multilineage reprogramming of astrocytes in adult mouse brains

by Medical Finance
May 19, 2022
0

A single protein can reverse the developmental clock on adult brain cells called astrocytes, morphing them into stem-like cells that...

Researchers investigate how messenger substances signal inflammation during damaged cell removal

GlyNAC supplementation can increase lifespan and improve multiple age-associated defects

by Medical Finance
May 19, 2022
0

Many people aspire to live longer, healthier lives. A researcher at Baylor College of Medicine, Dr. Rajagopal Sekhar, associate professor...

PhoreMost and POLARISqb announce a multi-target collaboration to investigate next-generation cancer therapies

Mechanical stress of confined migration makes cancer cells more aggressive

by Medical Finance
May 19, 2022
0

Squeezing through tight spaces makes cancer cells more aggressive and helps them evade cell death, shows a study published today...

Study: Multicenter Analysis of Neutrophil Extracellular Trap Dysregulation in Adult and Pediatric COVID-19. Image Credit: Luca9257 / Shutterstock.com

NETosis in COVID-19 and MIS-C

by Medical Finance
May 19, 2022
0

While the majority of infections with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) will recover, a significant minority progress...

Study reveals differential blood glycoprotein profiles in symptomatic and asymptomatic COVID-19 patients

Study reveals differential blood glycoprotein profiles in symptomatic and asymptomatic COVID-19 patients

by Medical Finance
May 19, 2022
0

As of March 9, 2022, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is the virus responsible for the...

Next Post
Bacterial biofilms use a developmental patterning mechanism seen in plants and animals

Rising temperatures lead to increased prevalence of Vibrio bacteria in UK waters

Study: Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant. Image Credit: creativeneko/Shutterstock

Effectiveness of prior infection in preventing reinfection with Omicron and other SARS-CoV-2 variants in Qatar

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Shift of lung macrophage composition is associated with COVID-19 disease severity and recovery. Image Credit: SciePro / Shutterstock.com
    Study suggests myeloid cell dysregulation is a driver of COVID-19 severity
  • Study: SARS-CoV-2 and its variants, but not Omicron, induces severe thymic atrophy and impaired T cell development. Image Credit: erhanyelekci/Shutterstock
    Study investigates the cause of lymphopenia as seen in COVID-19 patients
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply